Literature DB >> 12773167

Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function.

E Sim1, K Pinter, A Mushtaq, A Upton, J Sandy, S Bhakta, M Noble.   

Abstract

The arylamine N-acetyltransferases (NATs) are a unique family of enzymes that catalyse the transfer of an acetyl group from acetyl-CoA to the terminal nitrogen of hydrazine and arylamine drugs and carcinogens. The NATs have been shown to be important in drug detoxification and carcinogen activation, with humans possessing two isoenzymes encoded by polymorphic genes. This polymorphism has pharmacogenetic implications, leading to different rates of inactivation of drugs, including the anti-tubercular agent isoniazid and the anti-hypertensive drug hydralazine. Mice provide a good model for human NAT, allowing genetic manipulation of expression to explore possible endogenous roles of these enzymes. The first three-dimensional NAT structure was resolved for NAT from Salmonella typhimurium, and subsequently the structure of NAT from Mycobacterium smegmatis has been elucidated. These identified a 'Cys-His-Asp' catalytic triad (conserved in all NATs), which is believed to be responsible for the activation of the active site cysteine residue. As more genomic data become available, NAT homologues continue to be found in prokaryotic species, many of which are pathogenic, including Mycobacterium tuberculosis. The discovery of NAT in M. tuberculosis is particularly significant, since this enzyme participates in inactivation of isoniazid in the bacterium, with implications for isoniazid resistance. Structural studies on NAT proteins and phenotypic analyses of organisms (both mice and prokaryotes) following genetic modifications of the nat genes are leading to an understanding of the potentially diverse roles of NAT in endogenous and xenobiotic metabolism. These studies have indicated that NAT, particularly in Mycobacteria, has the potential to be a drug target. Combinatorial chemical approaches, together with in silico structural studies, will allow for advances in the identification of NAT substrates and inhibitors, both as experimental tools and as potential drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773167     DOI: 10.1042/bst0310615

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  13 in total

1.  Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.

Authors:  Peter Buchwald; Attila Juhász; Cynthia Bell; Márta Pátfalusi; John Howes; Nicholas Bodor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Berberine inhibits arylamine N-acetyltransferase activity and gene expression in Salmonella typhi.

Authors:  Lii-Tzu Wu; Mei-Fen Tsou; Chin-Chin Ho; Jing-Yuan Chuang; Hsiu-Maan Kuo; Jing-Gung Chung
Journal:  Curr Microbiol       Date:  2005-08-02       Impact factor: 2.188

3.  Arylamine N-acetyltransferase responsible for acetylation of 2-aminophenols in Streptomyces griseus.

Authors:  Hirokazu Suzuki; Yasuo Ohnishi; Sueharu Horinouchi
Journal:  J Bacteriol       Date:  2006-12-08       Impact factor: 3.490

4.  N-acetyltransferase 2 activity and folate levels.

Authors:  Wen Cao; Diana Strnatka; Charlene A McQueen; Robert J Hunter; Robert P Erickson
Journal:  Life Sci       Date:  2009-11-20       Impact factor: 5.037

5.  Probing the catalytic potential of the hamster arylamine N-acetyltransferase 2 catalytic triad by site-directed mutagenesis of the proximal conserved residue, Tyr190.

Authors:  Xin Zhou; Naixia Zhang; Li Liu; Kylie J Walters; Patrick E Hanna; Carston R Wagner
Journal:  FEBS J       Date:  2009-10-23       Impact factor: 5.542

6.  Case Study 10: A Case to Investigate Acetyl Transferase Kinetics.

Authors:  Jennifer L Dumouchel; Valerie M Kramlinger
Journal:  Methods Mol Biol       Date:  2021

7.  Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice.

Authors:  Sotiria Boukouvala; Naomi Price; Kathryn E Plant; Edith Sim
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

8.  Rapid birth-and-death evolution of the xenobiotic metabolizing NAT gene family in vertebrates with evidence of adaptive selection.

Authors:  Audrey Sabbagh; Julie Marin; Charlotte Veyssière; Emilie Lecompte; Sotiria Boukouvala; Estella S Poloni; Pierre Darlu; Brigitte Crouau-Roy
Journal:  BMC Evol Biol       Date:  2013-03-07       Impact factor: 3.260

9.  NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant.

Authors:  Nichola Johnson; Peter Bell; Vesna Jonovska; Marc Budge; Edith Sim
Journal:  BMC Med Genet       Date:  2004-03-17       Impact factor: 2.103

10.  Multiple advantageous amino acid variants in the NAT2 gene in human populations.

Authors:  Francesca Luca; Giuseppina Bubba; Massimo Basile; Radim Brdicka; Emmanuel Michalodimitrakis; Olga Rickards; Galina Vershubsky; Lluis Quintana-Murci; Andrey I Kozlov; Andrea Novelletto
Journal:  PLoS One       Date:  2008-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.